PP
PRVB

Paloma Partners’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Paloma Partners’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-22,449
Closed -$317K – 2599
2020
Q2 		$317K Buy
+22,449
New +$283K 0.01% 1453

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Paloma Partners's PRVB Position: Q3 2020 in Review

Paloma Partners sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2020, closing a stake of 22,449 shares — an estimated $317K sold.

Paloma Partners first reported a position in PRVB in Q2 2020 and held it in 1 quarter. The position peaked at $317K in Q2 2020. 100 funds tracked by Wall St. Rank hold PRVB as of Q3 2020.

  • Paloma Partners reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 22,449 Provention Bio, Inc. Common Stock shares in Q3 2020, an estimated $317K.
  • Paloma Partners first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Paloma Partners's Provention Bio, Inc. Common Stock position peaked at $317K in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.